Key result
Anakinra prompts partial regression of diffuse coronary aneurysms in an infant with refractory Kawasaki disease.
Why the study?
There is no consensus regarding optimal adjunctive therapeutics for refractory Kawasaki disease complicated by coronary artery aneurysms.
Does anakinra improve coronary aneurysms in infants with refractory Kawasaki disease?
Case Report (n=1)
Does anakinra improve coronary aneurysms in infants with refractory Kawasaki disease?
Anakinra may be a useful and safe adjunctive therapy for refractory Kawasaki disease complicated by coronary artery aneurysms.
May support adjunctive anakinra in refractory infant Kawasaki disease; leaves open confirmation of aneurysm regression in controlled trials.
Kawasaki disease is an acute self-limited vasculitis of unknown aetiology. The prognosis depends mainly on coronary damage. There is no consensus regarding optimal adjunctive therapeutics for refractory forms to treatment by intravenous immunoglobulins and corticosteroids. We report the case of an 18-month-old infant with refractory Kawasaki disease complicated by diffuse aneurysms of coronary arteries and successfully treated by anakinra with partial regression of coronary aneurysms.
No takes yet. Share an insight, caveat, or question.
Guillaume et al. (2018) conducted a case report in Refractory Kawasaki disease complicated by coronary artery aneurysm (n=1). Anakinra was evaluated on Regression of coronary aneurysms. Anakinra successfully treated an 18-month-old infant with refractory Kawasaki disease, leading to partial regression of diffuse coronary artery aneurysms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: